Carisma Therapeutics Inc.
Carisma Therapeutics Inc. is grouped at the issuer level across 1 linked ticker lifecycle, combining public listing, delisting, source, and shareholder outcome records from the archive.
Lifecycle Map
Issuer enters the archive
Dec 30, 2013Carisma Therapeutics Inc. is represented as an issuer-level entity with 1 linked public-market ticker lifecycle.
Delisting event
Dec 15, 2025Removed from listing - SEC Form 25 filed.
SourceCARM stopped trading
Dec 15, 2025CARM is linked to Carisma Therapeutics Inc. and ended with final status "merged".
Source
Entity Graph
Carisma Therapeutics Inc.issuedCARM
CARMlisted onNASDAQ
CARMresulted inmixed
Source-Backed Claims
- Eleven Biotherapeutics, Inc. held a Special Meeting of Stockholders on August 15, 2016, at WilmerHale LLP, Boston, Massachusetts.DEFM14A
- Stockholders of record as of June 27, 2016, were entitled to vote at the Special Meeting.DEFM14A
- The License Agreement between Eleven Biotherapeutics, Inc. and F. Hoffmann-La Roche Ltd was dated June 10, 2016.DEFM14A
- The total shares outstanding entitled to vote at the Special Meeting was 19,961,592 shares of common stock.DEFM14A
- The License Transaction Proposal requires approval by the affirmative vote of holders of a majority of the outstanding shares of common stock entitled to vote.DEFM14A
- The Board of Directors of Eleven Biotherapeutics, Inc. unanimously recommended that stockholders vote "FOR" the License Transaction Proposal.DEFM14A
- Roche will pay an up-front license fee of $7.5 million under the License Agreement, in addition to up to $262.5 million in milestone payments.DEFM14A
Associated Tickers
Public-market security lifecycles tied to this issuer record.